Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells

Olga Pastorino; Maria Teresa Gentile; Alessandro Mancini; Nunzio Del Gaudio; Antonella Di Costanzo; Adriana Bajetto; Paola Franco; Lucia Altucci; Tullio Florio; Maria Patrizia Stoppelli; Luca Colucci-D’Amato

doi:10.3390/cancers11060747

journal article Open Access May 29, 2019

Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells

Olga Pastorino Maria Teresa Gentile

Alessandro Mancini

Nunzio Del Gaudio Antonella Di Costanzo Adriana Bajetto Paola Franco

Lucia Altucci

Tullio Florio

Maria Patrizia Stoppelli Luca Colucci-D’Amato

Cancers Vol. 11 No. 6 pp. 747 · MDPI AG

View at Publisher Save 10.3390/cancers11060747

Abstract

Glioblastoma (GBM), a high-grade glioma (WHO grade IV), is the most aggressive form of brain cancer. Available treatment options for GBM involve a combination of surgery, radiation and chemotherapy but result in a poor survival outcome. GBM is a high-vascularized tumor and antiangiogenic drugs are widely used in GBM therapy as adjuvants to control abnormal vasculature. Vasculogenic mimicry occurs in GBM as an alternative vascularization mechanism, providing a means whereby GBM can escape anti-angiogenic therapies. Here, using an in vitro tube formation assay on Matrigel®, we evaluated the ability of different histone deacetylase inhibitors (HDACis) to interfere with vasculogenic mimicry. We found that vorinostat (SAHA) and MC1568 inhibit tube formation by rat glioma C6 cells. Moreover, at sublethal doses for GBM cells, SAHA, trichostatin A (TSA), entinostat (MS275), and MC1568 significantly decrease tube formation by U87MG and by patient-derived human GBM cancer stem cells (CSCs). The reduced migration and invasion of HDACis-treated U87 cells, at least in part, may account for the inhibition of tube formation. In conclusion, our results indicate that HDACis are promising candidates for blocking vascular mimicry in GBM.

Topics

No keywords indexed for this article. Browse by subject →

References

62

[1]

WHO, IARC (2019, March 10). World Cancer Report. Available online: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports.

[2]

Hanif "Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment" Asian Pac. J. Cancer Prev. (2017)

[3]

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

David N. Louis, Arie Perry, Guido Reifenberger et al.

Acta Neuropathologica 2016 10.1007/s00401-016-1545-1

[4]

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp, Warren P. Mason, Martin J. van den Bent et al.

New England Journal of Medicine 2005 10.1056/nejmoa043330

[5]

Furnari "Malignant astrocytic glioma: Genetics, biology, and paths to treatment" Genes Dev. (2007) 10.1101/gad.1596707

[6]

"Survival in glioblastoma: A review on the impact of treatment mdalities" Clin. Transl. Oncol. (2016) 10.1007/s12094-016-1497-x

[7]

Ruggiero "Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors" J. Neurooncol. (2013) 10.1007/s11060-013-1145-z

[8]

Zustovich "A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma" Anticancer Res. (2009)

[9]

Holmes "Trying to unravel the mysteries of chemobrain" Lancet Neurol. (2013) 10.1016/s1474-4422(13)70087-5

[10]

Gong "Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy" Neurology (2011) 10.1212/wnl.0b013e318212a89f

[11]

Singh "Identification of a cancer stem cell in human brain tumors" Cancer Res. (2003)

[12]

Identification of human brain tumour initiating cells

Sheila K. Singh, Cynthia Hawkins, Ian D. Clarke et al.

Nature 2004 10.1038/nature03128

[13]

Glioblastoma cancer stem cells – From concept to clinical application

Barbara E. Stopschinski, Christoph P. Beier, Dagmar Beier

Cancer Letters 2013 10.1016/j.canlet.2012.05.033

[14]

Lathia "Cancer stem cells in glioblastoma" Genes Dev. (2015) 10.1101/gad.261982.115

[15]

Bao "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response" Nature (2006) 10.1038/nature05236

[16]

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

Gentao Liu, Xiangpeng Yuan, Zhaohui Zeng et al.

Molecular Cancer 2006 10.1186/1476-4598-5-67

[17]

Eramo "Chemotherapy resistance of glioblastoma stem cells" Cell Death Differ. (2006) 10.1038/sj.cdd.4401872

[18]

Beier "Chemoresistance of glioblastoma cancer stem cells—Much more complex than expected" Mol. Cancer (2011) 10.1186/1476-4598-10-128

[19]

Hillen "Tumour vascularization: Sprouting angiogenesis and beyond" Cancer Metastasis Rev. (2007) 10.1007/s10555-007-9094-7

[20]

Ausprunk "Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis" Microvasc. Res. (1977) 10.1016/0026-2862(77)90141-8

[21]

The biology of VEGF and its receptors

Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter

Nature Medicine 2003 10.1038/nm0603-669

[22]

Carmeliet "VEGF as a key mediator of angiogenesis in cancer" Oncology (2005) 10.1159/000088478

[23]

Santarelli "Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain" Neurosurgery (2006) 10.1227/01.neu.0000222658.66878.cc

[24]

Holash "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF" Science (1999) 10.1126/science.284.5422.1994

[25]

Dome "Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance" J. Pathol. (2002) 10.1002/path.1124

[26]

Patan "Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis" Microvasc. Res. (1996) 10.1006/mvre.1996.0025

[27]

Burri "Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance" Dev. Dyn. (2004) 10.1002/dvdy.20184

[28]

Maniotis "Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry" Am. J. Pathol. (1999) 10.1016/s0002-9440(10)65173-5

[29]

Bao "Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor" Cancer Res. (2006) 10.1158/0008-5472.can-06-1010

[30]

Pallini "Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells" Nature (2010) 10.1038/nature09557

[31]

Wang "Glioblastoma stem-like cells give rise to tumour endothelium" Nature (2010) 10.1038/nature09624

[32]

Boisselier "A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry" Brain (2010) 10.1093/brain/awq044

[33]

Scully "Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas" J. Neurosci. (2012) 10.1523/jneurosci.2017-12.2012

[34]

Yao "Contribution of cancer stem cells to tumor vasculogenic mimicry" Protein Cell (2011) 10.1007/s13238-011-1041-2

[35]

Angara "Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma" Transl. Oncol. (2017) 10.1016/j.tranon.2017.04.007

[36]

Vredenburgh "Bevacizumab plus irinotecan in recurrent glioblastoma multiform" J. Clin. Oncol. (2007) 10.1200/jco.2007.12.2440

[37]

Kreisl "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma" J. Clin. Oncol. (2009) 10.1200/jco.2008.16.3055

[38]

Arbab "Vascular Mimicry: The Next Big Glioblastoma Target" Biochem. Physiol. (2015)

[39]

Sun "Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma" Cancer Lett. (2007) 10.1016/j.canlet.2006.08.016

[40]

Nagarajan "Epigenetic mechanisms in glioblastoma multiforme" Semin. Cancer Biol. (2009) 10.1016/j.semcancer.2009.02.005

[41]

Ropero "The role of histone deacetylases (HDACs) in human cancer" Mol. Oncol. (2007) 10.1016/j.molonc.2007.01.001

[42]

Wang "Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes" Cell (2009) 10.1016/j.cell.2009.06.049

[43]

Histone deacetylase inhibitors: molecular mechanisms of action

W S Xu, R B Parmigiani, P A Marks

Oncogene 2007 10.1038/sj.onc.1210620

[44]

Minucci "Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer" Nat. Rev. Cancer (2006) 10.1038/nrc1779

[45]

Bezecny "Histone deacetylase Inhibitors in glioblastoma: pre-clinical and clinical experience" Med. Oncol. (2014) 10.1007/s12032-014-0985-5

[46]

Gregoretti "Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis" J. Mol. Biol. (2004) 10.1016/j.jmb.2004.02.006

[47]

Didonna "The promise and perils of HDAC inhibitors in neurodegeneration" Ann. Clin. Transl. Neurol. (2015) 10.1002/acn3.147

[48]

Qiao "Advanced research on vasculogenic mimicry in cancer" J. Cell. Mol. Med. (2015) 10.1111/jcmm.12496

[49]

Arnaoutova "In vitro angiogenesis: Endothelial cell tube formation on gelled basement membrane extract" Nat. Protoc. (2010) 10.1038/nprot.2010.6

[50]

Francescone "Matrigel-based tube formation assay to assess the vasculogenic activity of tumor cells" J. Vis. Exp. (2011)

Showing 50 of 62 references

Cited By

43

Cell membrane-encased thylakoid as white light triggered PDT therapy for facile and targeted choroidal melanoma treatment

Jiahao Wang, Zhirong Chen · 2026

Bioactive Materials

Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities

Amanda L. Johnson, John Laterra · 2022

Frontiers in Oncology

Metrics

43

Citations

62

References

Details

Published: May 29, 2019
Vol/Issue: 11(6)
Pages: 747
License: View

Authors

O

Olga Pastorino

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy

M

Maria Teresa Gentile

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy

A

Alessandro Mancini

Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy; BioUp Sagl, 6900 Lugano, Switzerland

N

Nunzio Del Gaudio

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

A

Antonella Di Costanzo

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

A

Adriana Bajetto

Pharmacology Unit, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genova, 16132 Genova, Italy; IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy

P

Paola Franco

Institute of Genetics and Biophysics “A. Buzzati Traverso” (IGB-ABT), National Research Council of Italy, 80131 Naples, Italy

L

Lucia Altucci

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

T

Tullio Florio

Pharmacology Unit, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genova, 16132 Genova, Italy; IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy

M

Maria Patrizia Stoppelli

Institute of Genetics and Biophysics “A. Buzzati Traverso” (IGB-ABT), National Research Council of Italy, 80131 Naples, Italy

L

Luca Colucci-D’Amato

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; InterUniversity Center for Research in Neurosciences (CIRN), 80131 Naples, Italy

Funding

Regione Campania Award: FASE2-IDEAL

PRIN Award: 20152TE5PK

AIRC Award: 17217

POR Award: SATIN

FP7-BLUEPRINT Award: 282510

Lotta alle patologie concologiche Award: iCURE

progetti retrospettivi progetto MERCURIO Award: FESR

Università della Campania Luigi Vanvitelli Award: progetto VALERE,

BioUp Sagl Award: BioUp Sagl

Cite This Article

Olga Pastorino, Maria Teresa Gentile, Alessandro Mancini, et al. (2019). Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells. Cancers, 11(6), 747. https://doi.org/10.3390/cancers11060747

Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells

You May Also Like